BACKGROUND: In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. METHODS: Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state. RESULTS: Compared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons. CONCLUSIONS: The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.
BACKGROUND: In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. METHODS: Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state. RESULTS: Compared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons. CONCLUSIONS: The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.
Authors: Catherine Yen; Jacqueline E Tate; Terri B Hyde; Margaret M Cortese; Benjamin A Lopman; Baoming Jiang; Roger I Glass; Umesh D Parashar Journal: Hum Vaccin Immunother Date: 2014-04-22 Impact factor: 3.452
Authors: Patrick J Javid; Sabrina E Sanchez; Susan Jacob; Monica M McNeal; Simon P Horslen; Janet A Englund Journal: J Pediatric Infect Dis Soc Date: 2013-10-14 Impact factor: 3.164
Authors: Way Seah Lee; Benjamin Tze Ying Lim; Pei Fan Chai; Carl D Kirkwood; Jimmy Kok Foo Lee Journal: Hum Vaccin Immunother Date: 2012-09-28 Impact factor: 3.452
Authors: Sean T O'Leary; Umesh D Parashar; Lori A Crane; Mandy A Allison; Shannon Stokley; Brenda L Beaty; Michaela Brtnikova; Laura P Hurley; Allison Kempe Journal: Am J Prev Med Date: 2013-01 Impact factor: 5.043
Authors: Nonkululeko B Magagula; Mathew D Esona; Martin M Nyaga; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Mapaseka L Seheri; A Duncan Steele; David E Wentworth; M Jeffrey Mphahlele Journal: J Med Virol Date: 2014-05-20 Impact factor: 2.327